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COMMENTARY 
Clinical Trials of TCDD 
Gary Kayajanian 
1600 South Joyce Street, Suite 141 1, Arlington, VA 22202 
A patent (No. 6,444,698) has been issued recently allowing the use of 2,3,7,8- 
tetrachlorodibenzo-pdioxin (TCDD) as a promoter blocker of specific, named 
cancers in men and women as well as multiple cancers measured as total cancers.' 
Supporting the patent claim are the Kociba lifetime male and female rat feeding 
study (Kociba et  al. 1978) and three epidemiology studies identified below hereto- 
fore regarded as environmental rather than clinical based on the presentation of 
study data in the literature and/or their design. In this note I would like to utilize 
attributes associated with TCDD's activity to recast these epidemiology studies as 
clinical rather than environmental. These attributes include persistence of TCDD in 
humans (half-life equals 7.5 years, per Michalek et al. 1996) to a calculable and 
sufficiently constant TCDD body burden level, and a sufficiently long latency period 
to measure the effects of a chemical acting as a promoter blocker (Kayajanian 1997). 
In Kociba, 50 or  49 male and female rats were fed diets of 20, 200, or 2000 ppt 
TCDD, which does not persist in rats (Fries and Marrow 1975). Eighty-five males and 
86 females served as controls. When compared to the respective control, the mea- 
sure total cancers/animal was always reduced in each exposed group, and signifi- 
cantly reduced (p < 0.01) in each sex at  low and mid exposures (Kayajanian 1997). 
This study establishes TCDD as a potent anticarcinogen in rats. 
If TCDD behaves as an anticarcinogen in humans as it does in rats, at what stage 
of cancer creation does TCDD act? If TCDD were to block the final replicative step 
leading to a cancer diagnosis in humans, one would expect to observe a reduction 
in expected cancers in short order, say, within a year. If TCDD were to block the 
promotional step in cancer creation, the cancer reduction would take more time to 
register - several years, perhaps 5. If TCDD were to block an early step in cancer 
creation, like initiation, it might take 15, 20, or  more years to register the effect as 
a cancer reduction. These cancer reduction effects should continue for as many 
The patent may be accessed at http://pair.uspto.gov. The author is the patent holder. 
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years as the TCDD level in man remains sufficient. Of course, many of the exposures 
to TCDD have occurred in settings with contemporaneous exposures to many other 
chemicals assumed to act as cancer initiators. Their carcinogenic effects might mask 
the cancer preventative effects of TCDD 15, 20, or more years after the initial 
exposure to them and TCDD. 
TCDD AS A PROMOTER BLOCKER: USE OF THE SEVESO AND NIOSH 
DATA SETS FOR CLINICAL COMPARISONS 
The selection of subjects for a clinical trial is purposeful, designed to maximize 
the ability to observe any effect(s) of the TCDD exposure at trial. These maximized 
health benefits can better offset any adverse effects associated with the treatment. 
Tamoxifen, for example, touted to reduce breast cancer incidence but a known 
uterine carcinogen, was clinically tested in women more likely to develop breast 
cancer. 
In both the Seveso and NIOSH data sets, the TCDD-exposed populations were 
not selected for treatment and for that reason may be more representative of the 
general population than traditional trial groupings. Since TCDD persists in humans, 
the TCDD body burden level at any point in time can be backcalculated from later 
serum measurements. There is an assured constancy in man's daily exposure, even 
though it declines slowly over time. 
A clinical trial sufficiently matches exposed and unexposed subjects under cir- 
cumstances where the observations on the unexposed group serves as reference for 
the exposed cohort. Over time a trial would generate two ultimate fractions: the 
number of diseased individuals per cohort size for each group of subjects. In order 
to serve as a suitable control, the unexposed cohort is matched as closely as possible 
(except for exposure) to the exposed cohort. If a substantial latency period is 
required to observe the effect of the treatment on the disease in the exposed cohort, 
then each cohort would generate two fractions - one during and one after the 
latency period. Both exposed cohort fractions are perfectly matched to each other 
except for time; both unexposed cohorts also are perfectly matched to each other 
in the same way except for time. Consequently, any ratio of the exposed/unexposed 
fractions during and post latency are perfectly matched, even if the match of 
exposed and unexposed subjects does not meet a traditional clinical process stan- 
dard. If the ratio of the fractions of the two cohorts during and post latency differ 
significantly in the anticipated direction, this less than clinical trial should be viewed 
as a clinical success. 
I have made the claim that appropriate body burdens of TCDD act as a promoter 
blocker of cancers in man, an effect discernable about five years following exposure 
to TCDD. In the Seveso and NIOSH epidemiology data sets, the respective reference 
groups employed (matched by sex and age to within 5 years from a larger neighbor- 
ing Italian town and the U.S. population) would not meet the standard for a clinical 
trial in a non latency comparison. 
Nonlinearity in Biology, Toxicology, and Medicine. Vol. 1, No. 2, 2003. 
2
Dose-Response: An International Journal, Vol. 1 [2007], Iss. 2, Art. 3
https://scholarworks.umass.edu/dose_response/vol1/iss2/3
Clinical Trials of TCDD 
The 1993 Bertazzi et al. paper reports time stratified cancer morbidity data in the 
low TCDD exposed Seveso adults (group R) and unexposed cohort (nearby town) 
for several cancer categories, including corpus ulrm'- for the first 5 years and the 
second 5 years following exposure. In a population of more than 16,000 low- 
exposure women, 9 corpus uteri were observed in the first 5 years compared with 8.6 
observed in a size matched reference group. In the second 5 years, 0 c.or/)us ulmiwere 
observed in the R group women, compared with 13.4 observed in the same sized 
reference group. The during and post latency ratios that simplify to 9/8.6 and 0/ 
13.4, respectively, differ significantly from each other in the predicted direction (p 
< 0.0001). 
Primary liver cancer in R region males also displays this second 5-year ratio 
reduction. From unpublished data provided by Bertazzi, three primary liver cancers 
were observed in the first 5 years when 4.02 were expected from men in the 
unexposed cohort. In the second 5 years, 0 prirnary liver cancers were observed in 
R region men, when 7.00 were expected. The reduction is significant (p < 0.05). 
Total cancer incidence in these R region women is also reduced in the second 
five years (119 observed, when 143.2 were observed in the size matched nearby 
town) when compared to the first 5 years (193 observed in Seveso, when 186.5 were 
observed nearby), p < 0.06 (data conlmunicated by Bertazzi). 
A similar first-5/second-5-yearsemploy1nent-following-TCDDexposure a guinen t 
can be generated from the NIOSH cancer mortality data for total cancers: In  the 
first five years, 10 cancer deaths were observed when 11.76 were expected; in the 
second five years, 1 cancer death was observed when 5.56 were expected (p < 0.05) 
(Fingerhut et al. 1990). 
TCDD AS A PERSISTENT PROMOTER BLOCKER: USE OF THE 
OPERATION RANCH HAND (ORH) DATA SET FOR CLINICAL 
COMPARISON 
The ORH Study of Air Force veterans exposed to TCDD during their Southeast 
Asia duty tour was initially designed with paired TCDD-exposed and -unexposed 
airmen in *a peer-reviewed protocol. The ORH Study Manager abandoned the 
pairings and divided the exposed veterans into three categories based on TCDD 
body burden level, then compared cancer incidence in each category with that 
measure in the entire group of unexposed veterans (Ketchum r1 nl. 1999). In a 2001 
analysis of that data, I defined seven TCDD body burden ranges: nurnber 7 had the 
greatest TCDD body burden and the lowest cancer incidence (Kayajanian 2001). 
In a revised comparison more in keeping with the original ORH Study design, 
total non skin cancer incidence in group 7 veterans (with TCDD body h ~ ~ r d e n s  in 
excess of 128 ppt at duty tour's end), there were 11 veterans with cancer among 227 
veterans, which is lower (p < 0.06) than the incidence for the paired unexposed 
veterans (24/249), whom the ORH Study managers matched one- or two-to-one by 
sex, race, occupational classification, and same birth year. There are other TCDD- 
unexposed veterans matched by the ORH Study managers to the other exposed 
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veterans who also could have been matched to group 7 airmen: of 475 additional 
TClDD-tunexposed veterans, 38 developed a non-skin cancer. Matched against a 
larger unexposed cohort (62/724), the reduction observed in group 7 veterans (1 l /  
227) beconles significant (p  < 0.05). 
The matching unexposed veterans almost to a n ~ a n  have TCDD body burden 
levels between 0 to 10 ppt, when measurements were made in 1987. Roughly three 
out of seven TCDD-exposed veterans evince body burden measurements within the 
same 0 to 10 ppt range even though on paper they were classified as exposed to 
TCDD (Ketchum el al. 1999). Sonle of these veterans (164 men, 15 with non-skin 
cancer) would also match group 7 airmen. If this group enlarges the matching 
reference group (to 888 men, 77 with non-skin cancer), the reduction in cancer 
incidence associated with the group 7 veterans becomes more significant (p  < 0.04). 
To conclude, this commentary argues for the use of TCDD as a cancer prevention 
agent. In  Kociba, TCDD reduces total cancer incidence significantly in males and 
females at 540 and 5100 ppt. The timing of the cancer reductions in the Seveso and 
NIOSH data sets (years 6 to 10) suggests TCDD acts as a promoter blocker. Beyond 
10 years the cancer data are likely to be confounded by the incalculable effects of 
exposure to the other chen~icals in the Seveso and NIOSH chemical plants; so those 
cancer effects expected beyond 10 years were not relied on. In the ORH data set, 
significant total cancer incidence reductions are observed well beyond ten years, 
when there was a sufficient background of cancers to reduce and no  apparent excess 
of other, cancer initiating chenlicals like those in Seveso and NIOSH to overpower 
that observation. 
Taken together, these four data sets provide strong evidence that TCDD is a 
potent anticarcinogen not at every tissue site but whose activity is measurable as a 
significant reduction in total cancers. 
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